We are developing an expert-centered platform for abnormal blood cell morphology review, with the goal of making each review consistent, inspectable and traceable.
OUR PURPOSE
Build around the people who make the final judgment.
Blood morphology connects image interpretation with professional experience. AlignSight Medical brings those strengths together through an AI-assisted workflow that professionals can inspect, correct and review over time.
Our long-term vision is a blood morphology quality-management platform that can support validated workflows across institutions and imaging systems.
PROGRESS & MILESTONES
From a working prototype to the next stage.
2026
Working research prototype
The current research prototype connects image analysis, 16-category morphology pre-classification, expert correction and review records. Its categories include mature and immature cell types, labels suggestive of abnormal morphology, and artifacts.
A fixed held-out test evaluates the 16-category morphology classifier on 3,212 cell images. Clinical workflow and external validation are the next priorities.
Our team spans medical laboratory science, electrical and computer engineering, and intelligent healthcare. Work is organized around clinical needs, AI and data, software development, and commercialization.
I-Sin Chiu (Anita)
CEO / Certified Medical Laboratory Scientist (Taiwan)
Ben Fang
CTO
Hank Chui
Business Development Lead
Ryan Liu
AI Expert
David Lin
AI Expert
Vincent Huang
Certified Medical Laboratory Scientist (Taiwan)
01
Medical laboratory science
Clinical workflow, morphology review and validation design.
02
Electrical & computer engineering
Image analysis, AI models, software and data systems.
03
Intelligent healthcare
Connecting product design with clinical use and quality management.
MARKET & BUSINESS
Validate in Taiwan. Build for a broader opportunity.
Medical laboratory scientists and hematopathology teams are the intended users. Hospitals, health systems and clinical laboratories are the intended customers, with a planned B2B annual platform license and implementation, integration and support services.
Our first priority is to validate workflow value and adoption requirements with clinical partners in Taiwan. U.S. market exploration focuses on hospital hematology laboratories and reference laboratories with digital imaging capacity and a need for consistent, traceable morphology review.
DEVELOPMENT ROADMAP
A staged path from prototype to platform.
Next 12 months · goals
Clinical validation
Seek 2–3 clinical validation sites and 1–2 proof-of-concept collaborations. Define the study protocol, assess usability and review outcomes, and clarify the regulatory pathway.
Stage 02
Integration & external evidence
Develop imaging and LIS/HIS interfaces, multi-site validation and formal product governance.
Stage 03
Multi-site deployment
Build repeatable deployment and support processes, then evaluate international partnerships.
These are development goals, subject to evidence, partner requirements and regulatory review. Pilot sites and proof-of-concept collaborations are targets, not completed partnerships.
COLLABORATION
Build the next stage with us.
We are seeking clinical and industry partners to validate YMCA and develop its path to deployment.
Clinical validation partners
Hematology laboratories and morphology experts for authorized, de-identified images, expert annotations, usability studies and workflow comparisons.
Imaging & integration partners
Microscope-camera and scanner partners, LIS/HIS integrators and security specialists for compatibility testing and hospital deployment planning.
Product & commercialization partners
Medtech investors, regulatory and quality advisors, and international partners to support validation, product development and market access.